Structure CEO on Obesity Drugs: Oral Pills Are the Solution

The CEO of Structured Therapeutics discusses the company's efforts in developing an oral medication for obesity, aiming to address accessibility issues and improve patient adherence compared to injectable treatments. The company is in mid-stage trials and anticipates significant breakthroughs by 2025. They are exploring partnerships for commercialization and are focused on making medicines affordable. The discussion also covers M&A interest, pricing strategies, and geopolitical risks, particularly concerning US-China relations.

What is the CEO's perspective on the accessibility of obesity medications?

What strategies has Structured Therapeutics implemented to mitigate geopolitical risks?

How does the CEO view the global nature of obesity and its solutions?